India’s Syngene International completed site upgrades to add a dedicated peptide laboratory in Bengaluru and introduced advanced automation across DMPK and direct‑to‑biology (D2B) workflows. The facility supports linear and cyclic peptides, peptide‑drug conjugates and synthesis scale‑up to 800 mmol, with six automated peptide synthesizers operating in parallel. Syngene said automation will cut DMPK turnaround from five days to three, improve cost efficiency by ~30% and triple sample capacity, accelerating hit‑to‑lead timelines. The investments reflect a broader industry push to shorten discovery cycles and improve reproducibility in peptide and biologics discovery.